Correspondence
Emergency department visits after intravitreal bevacizumab and ranibizumab injections in diabetic patients
Bevacizumab (Avastin; Genentech, San Francisco, CA, USA) and ranibizumab (Lucentis; Genentech) are both inhibitors of vascular endothelial growth factor (VEGF). They are used intravitreally in the treatment of a variety of ocular diseases including age-related macular degeneration (AMD),1,2 diabetic macular edema (DME),3–7 proliferative retinopathy,8 retinal vein occlusion,9 and others.10,11
